Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 135 entries
View as:

Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT02470871 Org: User:
Start: 07/31/15 End: 10/31/16 Due: 10/31/17

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

Phase: N/A Priority: Normal
NCT ID: NCT00168103 Org: User:
Start: 06/30/05 End: 12/31/07 Due: 12/31/08

Haemocomplettan® P During Aortic Replacement

Phase: N/A Priority: Normal
NCT ID: NCT00701142 Org: User:
Start: 06/30/08 End: 04/30/10 Due: 04/30/11

Patient Registry Study of Berinert® in Normal Clinical Practice

Phase: N/A Priority: Normal
NCT ID: NCT01108848 Org: User:
Start: 04/30/10 End: 04/30/14 Due: 04/30/15

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

Phase: N/A Priority: Normal
NCT ID: NCT04672733 Org: User:
Start: 06/10/22 End: 12/31/27 Due: 12/31/28

Prothrombin Complex Concentrate for Anticoagulant Reversal

Phase: N/A Priority: Normal
NCT ID: NCT00168077 Org: User:
Start: 09/30/05 End: 11/30/06 Due: 11/30/07

A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04082754 Org: User:
Start: 11/28/19 End: 11/14/23 Due: 11/14/24

A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

Phase: N/A Priority: Normal
NCT ID: NCT00701545 Org: User:
Start: 02/29/08 End: 04/30/09 Due: 04/30/10

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Phase: N/A Priority: Normal
NCT ID: NCT03033745 Org: User:
Start: 02/01/17 End: 12/14/18 Due: 12/14/19

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Phase: N/A Priority: Normal
NCT ID: NCT06699849 Org: User:
Start: 07/11/25 End: 04/04/28 Due: 04/04/29

Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00867516 Org: User:
Start: 10/31/08 End: 12/31/09 Due: 12/31/10

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Phase: N/A Priority: Normal
NCT ID: NCT00751621 Org: User:
Start: 08/31/08 End: 12/31/11 Due: 12/31/12

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

Phase: N/A Priority: Normal
NCT ID: NCT03972280 Org: User:
Start: 07/04/19 End: 10/04/22 Due: 10/04/23

Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

Phase: N/A Priority: Normal
NCT ID: NCT04138485 Org: User:
Start: 12/20/19 End: 09/16/20 Due: 09/16/21

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01490450 Org: User:
Start: 12/31/11 End: 06/30/15 Due: 06/30/16

Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults

Phase: N/A Priority: Normal
NCT ID: NCT03375606 Org: User:
Start: 01/10/18 End: 06/22/20 Due: 06/22/21

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT03744910 Org: User:
Start: 10/14/19 End: 04/08/24 Due: 04/08/25

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT02484638 Org: User:
Start: 07/23/15 End: 03/28/18 Due: 03/28/19

Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert

Phase: N/A Priority: Normal
NCT ID: NCT01467947 Org: User:
Start: 11/30/11 End: 10/31/14 Due: 10/31/15

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT03805789 Org: User:
Start: 03/27/19 End: 10/18/29 Due: 10/18/30

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

Phase: N/A Priority: Normal
NCT ID: NCT06806657 Org: User:
Start: 03/19/25 End: 06/15/26 Due: 06/15/27

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT02172950 Org: User:
Start: 10/13/14 End: 01/19/21 Due: 01/19/22

Extension Study of Biostate in Subjects With Von Willebrand Disease

Phase: N/A Priority: Normal
NCT ID: NCT01224808 Org: User:
Start: 10/31/10 End: 03/31/14 Due: 03/31/15

Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Phase: N/A Priority: Normal
NCT ID: NCT00168025 Org: User:
Start: 09/30/04 End: 03/31/06 Due: 03/31/07

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05306275 Org: User:
Start: 04/04/22 End: 09/27/22 Due: 09/27/23